Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
Rapid Commun Mass Spectrom ; 38(9): e9728, 2024 May 15.
Article in English | MEDLINE | ID: mdl-38482917

ABSTRACT

RATIONALE: Acute renal failure (ARF) is one of the most serious complications of cardiopulmonary bypass (CPB) surgery. Serum creatinine level is a key compound examined to understand whether renal function is normal. However, its level may vary based on age, gender, race, muscle mass, nutrition, and drugs taken by an individual. In addition, it may not be detected without a 50% reduction in renal function and may lead to delays in treatment. New markers are needed for early diagnosis of ARF. They were determined for early diagnosis of ARF after CPB. Metabolic differences in plasma samples of individuals who developed and did not develop ARF after cardiopulmonary bypass were determined. METHODS: This study was the first to perform an untargeted metabolomics analysis for early diagnosis of ARF after CPB surgery. Plasma samples were taken from 105 patients (9 ARF patients) at five time points to identify the time at which a more accurate ARF diagnosis can be made. A total of 687 samples, including quality control samples, were analyzed. RESULTS: Two hundred twenty-six metabolites were identified using retention index libraries. Based on the statistical evaluations, tryptophan, threonine, and methionine were found in lower concentrations in patients with ARF compared to the control group at all time points. Whereas gluconic acid, hypoxanthine, and lactic acid showed a decreasing trend over time, longitudinal analysis showed that cysteine, hippuric acid, and uric acid levels increased over time in the ARF group. CONCLUSIONS: These metabolites are candidate biomarkers for early diagnosis of ARF as well as biomarkers for tracking the recovery of ARF patients.


Subject(s)
Acute Kidney Injury , Cardiopulmonary Bypass , Humans , Cardiopulmonary Bypass/adverse effects , Acute Kidney Injury/diagnosis , Acute Kidney Injury/etiology , Biomarkers , Time Factors
3.
Turk Gogus Kalp Damar Cerrahisi Derg ; 31(1): 37-44, 2023 Jan.
Article in English | MEDLINE | ID: mdl-36926145

ABSTRACT

Background: The aim of this study was to compare our experience of left ventricular assist device implantation via minimally invasive left thoracotomy with off-pump versus on-pump technique. Methods: Between June 2013 and April 2020, nine patients (8 males, 1 female; mean age: 47±11.9 years; range, 30 to 61 years) who underwent off-pump left ventricular assist device implantation and nine patients (8 males, 1 female; mean age: 47±11.4 years; range, 29 to 60 years) who underwent on-pump minimally invasive left thoracotomy were retrospectively analyzed. Postoperative outcomes and mid-term results of both groups were evaluated. Results: Outflow graft was anastomosed to the ascending aorta with J-sternotomy in all patients. The median duration of intubation and intensive care unit stay were one (IQR: 1.5) day and eight (IQR: 6.5) days in the off-pump group, respectively and one (IQR: 0) day and seven (IQR: 7) days in the on-pump group, respectively. Intra-aortic balloon pump was needed during the weaning of cardiopulmonary bypass in one (11%) of the patients in both groups. Postoperative right ventricular failure was observed in two (22%) patients in the offpump group who were treated medically and recovered. There was no need for revision due to bleeding or postoperative extracorporeal membrane oxygenator implantation in either group. In the off-pump group, three patients underwent heart transplantation after median 854 (IQR: 960) days. Three patients died one month, two and four years after implantation. Three patients were still alive with left ventricular assist device and were being uneventfully followed for 365, 400, and 700 days after implantation. Conclusion: Off-pump technique is safe and feasible option for implantation of left ventricular assist device via minimally invasive left thoracotomy.

4.
J Biosci ; 472022.
Article in English | MEDLINE | ID: mdl-34951407

ABSTRACT

Atherosclerosis is one of the main reasons of cardiovascular diseases, the most common cause of death in the world. NRF2 is a critical transcriptional factor that regulates oxidative stress response and contributes to the pathogenesis of atherosclerosis. This study aims to compare the expression levels of miR-34a, miR-125b, miR- 221 and NRF2 in blood samples of patients with atherosclerosis and of controls to find a novel link between microRNAs, oxidative stress and atherosclerosis. miR-34a, miR-125b, miR-221 and NRF2 relative expressions were analysed in 26 atherosclerosis patients and 25 healthy controls by q-RT-PCR assay. The receiver operating characteristic curve (ROC) was used to assess the diagnostic values of miR-34a, miR-125b, miR-221 and NRF2 by comparing the area under the curves (AUC) to differentiate between atherosclerosis and control samples. miR-34a and NRF2 were significantly upregulated, whereas miR-125b and miR-221 were significantly downregulated in patients compared with healthy controls. The ROC curves suggested high diagnostic value of miR-221 (AUC: 0.7477), miR-125b (AUC: 0.8523) and NRF2 (AUC: 0.838) for detection of atherosclerosis. Our results suggest that circulating miR-34a, miR-125b and miR-221 levels can be used as novel biomarkers for detection of atherosclerosis by targeting NRF2.


Subject(s)
Atherosclerosis , MicroRNAs , Antioxidants , Atherosclerosis/genetics , Biomarkers , Humans , MicroRNAs/genetics , NF-E2-Related Factor 2/genetics
5.
Int J Artif Organs ; 44(12): 972-979, 2021 Dec.
Article in English | MEDLINE | ID: mdl-33971762

ABSTRACT

BACKGROUND: We analyzed patients with left ventricular assist device (LVAD) related and specific infection, and aimed to determine whether surgical technique implantation affect the frequency of infection. METHODS: We retrospectively analyzed the data of 99 patients who received LVAD at our department between June 2013 and June 2019. Patients were divided into two groups according to the surgical technique. Group A (n = 58) was conventional sternotomy (CS) and group B (n = 41) was on-pump minimally invasive left thoracotomy (MILT). Demographics, preoperative risk factors, LVAD infections, surgical incision site, driveline site, and outcomes were compared between these two groups. RESULTS: Mean follow up time was 589 ± 480 (31-2171) days. Infection was detected in 34% (41/99) of LVAD patients. Admission to emergency department and intensive care unit (ICU) in last 6 months were significantly higher in MILT group. There was no difference between the two groups in terms of driveline exit site infection (CS: 28%, MILT: 27%) (p > 0.05). Seven (17%) patients had infection in the thoracotomy incision site area in the MILT group. The rate of ICU hospitalization in the last 6 months was seen as the only independent risk factor increasing the frequency of infection (R = 0.30; p = 0.016). Survival analysis at 60 days, 1 year and 2 years showed no difference between the two groups (p = 0.09). CONCLUSIONS: Despite advances in pump technology and surgical technique, infection is still an important cause of mortality and morbidity.


Subject(s)
Heart Failure , Heart-Assist Devices , Minimally Invasive Surgical Procedures , Prosthesis-Related Infections/epidemiology , Heart Failure/surgery , Humans , Prosthesis-Related Infections/prevention & control , Retrospective Studies , Sternotomy/adverse effects , Thoracotomy/adverse effects
6.
Artif Organs ; 44(12): 1251-1258, 2020 Dec.
Article in English | MEDLINE | ID: mdl-32663321

ABSTRACT

Continuous-flow intracorporeal left ventricular assist devices (CF-LVAD) are used more frequently in the pediatric population. One of the major complications of CF-LVAD is cerebrovascular events (CVEs). Limited information is available on this complication in pediatric patients. We hereby present our experience on CVEs in children under CF-LVAD support in our institution. A retrospective, single center review of 21 patients younger than 19 years of age who underwent CF-LVAD implantation between June 2014 and September 2018 was performed. Patients on biventricular support and extracorporeal devices were excluded. Cerebrovascular accidents (CVAs)-ischemic or hemorrhagic-were investigated. CVE was confirmed by brain computed tomographic scan. Of 21 pediatric patients, 11 were male. Mean BSA was 1.05 ± 0.41 m2 and mean age was 11.05 ± 4.07 years. Dilated cardiomyopathy was the leading cause of heart failure. The patients were implanted with HeartWare hVAD (n = 19), HeartMate II (n = 1), and HeartMate 3 (n = 1). Mean support time was 421 ± 448 (18-1460) days. Target international normalized ratio was between 2.5 and 3.0. Nine (43%) patients underwent transplantation, one patient recovered with subsequent device explantation. Four (17%) patients were still on support. One patient (5%) died in the early postoperative period and six (28%) patients died on VAD support after a mean duration of 194 days. There were overall five cerebral hemorrhagic strokes in four patients (0.2 events per patient-year). CVA occurred between 250 and 1320 days (mean 600 days). No ischemic stroke was documented. Only one (20%) patient died after hemorrhagic stroke; the other three patients recovered and were discharged from the hospital with minor sequelae. Incidence of CVE in children on CF-LVAD is relatively low compared with adults on VAD and severity of stroke is milder than adult population.


Subject(s)
Heart Failure/surgery , Heart-Assist Devices/adverse effects , Postoperative Complications/epidemiology , Prosthesis Implantation/adverse effects , Stroke/epidemiology , Adolescent , Cardiomyopathy, Dilated/complications , Cardiomyopathy, Dilated/surgery , Child , Child, Preschool , Female , Heart Failure/etiology , Heart Failure/mortality , Humans , Male , Postoperative Complications/diagnosis , Postoperative Complications/etiology , Prosthesis Implantation/instrumentation , Severity of Illness Index , Stroke/diagnosis , Stroke/etiology , Tomography, X-Ray Computed/statistics & numerical data , Treatment Outcome
7.
Int J Antimicrob Agents ; 21(4): 350-3, 2003 Apr.
Article in English | MEDLINE | ID: mdl-12672582

ABSTRACT

Although the efficacy of ceftriaxone in typhoid fever is well documented, the precise duration of ceftriaxone therapy in children with typhoid fever is not established and varies from 3 to 14 days in the literature. In a prospective, randomized study ceftriaxone was compared with chloramphenicol for treatment of 72 children who had bacteriologically confirmed typhoid fever. Ceftriaxone was given at a dose of 75 mg/kg per day (maximally 2 g/day) intravenously, in two doses until defervescence and continued 5 days after that time. Chloramphenicol was given at a dose of 75 mg/kg per day (maximally 2 g/day) in four doses for 14 days. Mean defervescence time was in 5.4 days in the ceftriaxone group and 4.2 days in the chloramphenicol group (P=0.04). Clinical cure without complications was achieved in all patients in both groups. No patient relapsed in the ceftriaxone group, and four patients relapsed in the chloramphenicol group (P=0.048). The overall results of this study suggest that a flexible-duration of ceftriaxone therapy given until defervescence time, followed by an additional 5 days of therapy is a reasonable alternative to conventional 14-day chloramphenicol treatment in children with typhoid fever.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Ceftriaxone/therapeutic use , Chloramphenicol/therapeutic use , Drug Administration Schedule , Typhoid Fever/drug therapy , Adolescent , Child , Child, Preschool , Female , Humans , Male , Prospective Studies , Randomized Controlled Trials as Topic , Typhoid Fever/blood
SELECTION OF CITATIONS
SEARCH DETAIL
...